South African biopharmaceutical company Biovac has inaugurated a new state-of-the-art vaccine formulation and fill-finish laboratory in Cape Town, a major step toward strengthening Africa’s vaccine manufacturing capacity and reducing dependence on imports.
The facility, unveiled on Thursday, is part of Biovac’s ongoing expansion to scale local production of vaccines and other biological products in collaboration with global partners such as Pfizer and BioNTech, according to a report by Reuters. The company said the new lab would enhance its ability to produce vaccines for diseases such as pneumonia, COVID-19, and meningitis, serving both South Africa and the broader African continent.
Speaking at the launch, Biovac CEO Morne du Plessis said the investment demonstrates the company’s long-term vision to make Africa self-sufficient in vaccine supply. “This new facility marks a historic milestone for African vaccine sovereignty. It strengthens our capacity to respond swiftly to outbreaks and improve public health resilience across the continent,” he said, as reported by Bloomberg.
The development comes amid renewed global efforts to decentralize vaccine manufacturing, a priority reinforced by the African Union’s target to produce 60% of vaccines locally by 2040, up from less than 1% currently. The World Health Organization (WHO) has also praised Biovac’s progress as a model for sustainable vaccine production partnerships in emerging markets.
Biovac, which is partly owned by the South African government, plans to increase its workforce by 30% over the next two years as operations ramp up. The new facility is expected to significantly reduce vaccine procurement costs for African countries and create new opportunities for regional collaboration in health innovation.
